SCHEMBL25781534

SCHEMBL25781534

NC(N)(c1ccc(Nc2ccccc2-c2nnn(CCO)n2)cc1)C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ABCG2 Q9UNQ0 2/20 0.39
▸ MAPT P10636 3/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ DDX3X O00571 1/20 0.38
▸ KMT2A Q03164 4/20 0.37
▸ MEN1 O00255 3/20 0.37
▸ TSHR P16473 3/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ KDM4E B2RXH2 3/20 0.37
▸ HPGD P15428 3/20 0.37
▸ HSD17B10 Q99714 2/20 0.37
▸ MAOB P27338 1/20 0.36
▸ TAS2R14 Q9NYV8 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ ATM Q13315 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20552643 0.90 ABCG2 (0.47) ABCG2MAPTSMN1; SMN2DDX3XALDH1A1
SCHEMBL25788929 0.85 HPGD (0.41) MAPTSMN1; SMN2DDX3XKMT2AMEN1
SCHEMBL20552347 0.84 ABCG2 (0.46) ABCG2MAPTSMN1; SMN2DDX3XALDH1A1
SCHEMBL21749262 0.83 ATM (0.43) SMN1; SMN2KMT2AMEN1TSHRHSD17B10
SCHEMBL21764731 0.83 SMN1; SMN2 (0.42) ABCG2MAPTSMN1; SMN2KMT2AMEN1
SCHEMBL20552594 0.83 TAS2R14 (0.55) ABCG2MAPTSMN1; SMN2DDX3XTSHR
SCHEMBL20553560 0.82 ABL1 (0.45) MAPTSMN1; SMN2TSHRMAOBLMNA
SCHEMBL20552728 0.82 ATM (0.39) ABCG2MAPTSMN1; SMN2DDX3XKMT2A
SCHEMBL20552265 0.81 ABCG2 (0.45) ABCG2MAPTSMN1; SMN2DDX3XALDH1A1
SCHEMBL20551735 0.81 TP53 (0.49) MAPTSMN1; SMN2KMT2AMEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF TEAD1, TEAD4, TEAD2 ABCG2 2217/4885MAPT 516/4885SMN1; SMN2 3035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback